| Literature DB >> 19014507 |
Aikaterini Papagianni1, Panagiotis Oulis2, Thomas Zambelis1, Panagiotis Kokotis1, George C Koulouris2, Nikos Karandreas1.
Abstract
BACKGROUND: Peroneal nerve is susceptible to injuries due to its anatomical course. Excessive weight loss, which reduces the fatty cushion protecting the nerve, is considered a common underlying cause of peroneal palsy. Other predisposing factors, such as prolonged postures, traumas of the region or concomitant pathologies (for example diabetes mellitus) contribute to the nerve damage. This study aims to reveal the multiple predisposing factors of peroneal nerve mononeuropathy after substantial weight loss that coexist in psychiatric patients and to make suggestions on their management.Entities:
Year: 2008 PMID: 19014507 PMCID: PMC2599894 DOI: 10.1186/1749-7221-3-24
Source DB: PubMed Journal: J Brachial Plex Peripher Nerve Inj ISSN: 1749-7221
Clinical data
| Patient | Sex | Psychiatric illness | Duration of psychiatric illness/number of previous hospitalizations | Main presenting symptom | Medications |
| |||
|---|---|---|---|---|---|---|---|---|---|
| 1 | Male | 57 | Major depressive episode in the context of a major depressive disorder | 7 months/2 hospitalizations. | 71/12/16.9% | 20 | Footdrop R, weakness of dorsiflexor muscles R. | maprotiline amitriptyline, diazepam, levomepromazine | |
| 2 | Male | 43 | Schizophrenic disorder | 23 years/none | 70/20/22.2% | 45 | Footdrop L | olanzapine, haloperidol, biperiden | |
| 3 | Male | 29 | Schizophrenic disorder | 6 years/2 hospitalizations | 68/20/22.7% | 18 | Weakness R | trifluoperazine, amitriptyline biperiden. | |
| 4 | Male | 62 | Major depressive episode in the context of a major depressive disorder | 1 year/1 hospitalization | 67/18/21.2% | 55 | Weakness of dorsiflexor muscles L | amitriptyline, clomipramine, chlorpromazine, quazepam. | |
| 5 | Male | 36 | Major depressive episode in the context of a major depressive disorder | 4 years/none | 92/23/20% | 20 | Weakness of dorsiflexor muscles L > R | clomipramine, sertraline | |
| 6 | Female | 73 | Major depressive episode in the context of a major depressive disorder | 2 years/1 hospitalization | 66/10/13.2% | 45 | Weakness of dorsiflexor muscles R | paroxetine, mirtazapine | |
| 7 | Male | 38 | Schizophrenic disorder | 2 years/2 hospitalizations | 70/13/15.6% | 60 | Footdrop L, weakness of dorsiflexor muscles L. | aripiprazole, olanzapine | |
| 8 | Male | 41 | Schizophrenic disorder | 21 years/3 hospitalizations | 118/35/22.9% | 7 years (2520) | sensory deficits R | risperidone, clomipramine, bromazepam | |
| 9 | Male | 43 | Major depressive episode in the context of a major depressive disorder | 20 years/1 hospitalization | 106/12/11.3% | 90 | Footdrop R, weakness of dorsiflexor muscles R | venlafaxine hydrochloride, levomepromazine, quetiapine fumarate, escitalopram, clorazepate dipotassium, lamotrigine | none |
Motor and Sensory (antidromic method) nerve conduction study of the peroneal nerve, using superficial recording electrodes
| Patient | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48 | 46 | 48 | 46 | 4.0 | 1.0 | 4.0 | 3.0 | 4.0 | 4.2 | 45 | 44 | 7 | 5 | 2.9 | 3.1 | |
| 32 | 48 | 47 | 49 | 0.5 | 4.3 | 2.5 | 5.0 | 3.6 | 4.0 | 51 | 52 | 4 | 16 | 2.9 | 2.5 | |
| 46 | 35 | 45 | 37 | 6 | 0.5 | 7.0 | 6.0 | 4.7 | 4.7 | 50 | 45 | 30 | 15 | 2.7 | 3 | |
| 32 | 49 | 50 | 52 | 0.2 | 4 | 2.5 | 3.0 | 4.1 | 4.8 | 50 | 50 | 6 | 6 | 2.4 | 2.5 | |
| 14 | 25 | 39 | 42 | 0.5 | 0.5 | 4.0 | 5.0 | 4.5 | 4.0 | 40 | 40 | 4 | 5 | 3.7 | 3.1 | |
| 54 | 53 | 53 | 51 | 7.0 | 2.0 | 7.0 | 2.4 | 3.5 | 4.0 | 51 | 50 | 14 | 12 | 2.8 | 2.6 | |
| 46 | 46 | 46 | 44 | 0.8 | 6.0 | 2.0 | 6.0 | 4.0 | 4.0 | 46 | 50 | 5 | 11 | 2.8 | 2.6 | |
| 53 | 45 | 50 | 47 | 6.0 | 2.5 | 6.0 | 2.3 | 3.9 | 4.5 | 55 | 57 | 9 | 8 | 2.4 | 2.6 | |
| 50 | 35 | 48 | 46 | 5 | 1 | 6 | 5 | 4 | 4.2 | 50 | 44 | 9 | 4 | 2.8 | 3.6 | |
1 Lower normal limit 42 m/sec. The lower normal limit of MCV and SCV indicative of axonal damage is 29.5 m/s
2 Lower normal limit 3 mV
3 Lower normal limit 42 m/sec
4 Lower normal limit 5 μV
Suggestions on patients' management
| First Evaluation | After the establishment of the diagnosis of peroneal nerve mononeuropathy | Preventive means |
|---|---|---|
| Detailed history; overcome obstacles in communication (onset of symptoms, weight loss, tendency to retain prolonged postures, e.g. squatting, legs crossed, is the patient bed-bound) | Information of medical and nursing staff in psychiatric units | |
| Complete clinical neurological examination | Patients' weight monitoring, establishment of well-balanced, nutritious dietary plan | |
| Reference for neurophysiological and electromyographic examination | Mobilization of patients and avoidance of prolonged postures |